Atazanavir/Ritonavir (n=10) Darunavir/Ritonavir (n=10)
Demographics      
Male, n (%)   4 (40) 6 (60)
Mean age, years (SE)   33 (4.6) 44 (5.7)
No previous smoking, n (%)   2 (20) 1 (10)
Family history, n (%) cardiovascular disease 3 (30) 4 (40)
  hypercholesterolaemia 1 (10) 1 (10)
Clinical measures      
Mean blood pressure, mmHg (SE) systolic 109 (3) 114 (4)
  diastolic 69 (2) 72 (3)
Heart rate, beats/minute (SE)   70 (3) 69 (3)
Height, m (SE)   1.71 (2.5) 1.78 (2.2)
Body mass index, kg/m2 (SE)   23 (0.5) 24 (1.1)
Fasting blood analytes      
Triglycerides, mmol/L (SE)   0.7 (0.1) 1.0 (0.2)
Total cholesterol, mmol/L (SE)   4.3 (0.2) 4.4 (0.3)
HDL cholesterol, mmol/L (SE)   1.4 (0.1) 1.2 (0.1)
LDL cholesterol, mmol/L (SE)   2.7 (0.2) 2.7 (0.3)
Total:HDL cholesterol (SE)   3.2 (0.2) 3.8 (0.4)
Bilirubin, ┬Ámol/L (SE)   10 (0.8) 9 (1.3)
Glucose, mmol/L (SE)   4.5 (0.1) 5.0 (0.3)
C-reactive protein, mg/L (SE)   1.6 (0.9) 1.7 (0.8)
D-dimer, mg/L (SE)   0.4 (0.2) 0.3 (0.1)
SE: standard error of the mean; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Table 1: Baseline characteristics and parameters of study participants.